Drug company payment disclosures have limited transparency, but find that they are increasing in value and are targeted at select patient organisations
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529850 | PMC |
| http://dx.doi.org/10.1136/bmj.l1806 | DOI Listing |
Publication Analysis
Top Keywords
patient organisations
8
exposing drug
4
drug industry
4
industry funding
4
funding patient
4
organisations drug
4
drug company
4
company payment
4
payment disclosures
4
disclosures limited
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!